LH Stock Recent News

Labcorp Holdings Inc. LH, or Labcorp's strong focus on key areas such as oncology, women's health, autoimmune disease and neurology is poised to help it grow in the upcoming quarters. The company maintains a steady pipeline of potential deals that support its financial strategy and will enhance its organic growth.

LOS ANGELES, June 02, 2025 (GLOBE NEWSWIRE) -- InStride , a leading provider of strategic education and skilling solutions, has facilitated a unique partnership between Arizona State University's College of Health Solutions and Labcorp, a global leader of innovative and comprehensive laboratory services, to launch a Master of Science in Cytology. ASU's online graduate program addresses the severe shortage of cytotechnologists—specialists essential to cancer detection and diagnostics.

New test offerings target solid tumors and hematologic malignancies Enhanced biopharma services support accelerated clinical trials and companion diagnostic development BURLINGTON, N.C. , May 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio.

Labcorp (LH) reported earnings 30 days ago. What's next for the stock?

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Labcorp (LH) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.73 per share. This compares to earnings of $3.68 per share a year ago.

Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C. , April 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.

Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dublin, April 11, 2025 (GLOBE NEWSWIRE) -- The "Genetic Screening Testing for Preventive Health Market - A Global and Regional Analysis: Focus on Test Type, Technology, Application, End User and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The market for genetic screening testing in preventive health has been experiencing rapid growth, driven by driving factors such as technological advancements, increased consumer interest in personalized medicine, and the rise of preventive healthcare strategies. Several key factors influence the expansion of the genetic screening testing for preventive health market. Improvements in genetic testing technologies, such as next-generation sequencing (NGS), have made these tests more accessible, cost-effective, and accurate. Growing consumer awareness of the benefits of early detection, rising healthcare costs, and an increasing focus on prevention have further fuelled the demand.

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease.